Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 49 to 60 of 70 entries
Sorted by: Best Match Show Resources per page
Prognosis of Interval Distant Metastases After Neoadjuvant Chemoradiotherapy for Esophageal Cancer.

The Annals of thoracic surgery

Kroese TE, Dijksterhuis WPM, van Rossum PSN, Verhoeven RHA, Mook S, Haj Mohammad N, Hulshof MCCM, van Berge Henegouwen MI, van Oijen MGH, Ruurda JP, van Laarhoven HWM, van Hillegersberg R.
PMID: 33610543
Ann Thorac Surg. 2021 Feb 18; doi: 10.1016/j.athoracsur.2021.01.061. Epub 2021 Feb 18.

BACKGROUND: In esophageal cancer patients, distant metastases develop between the start of neoadjuvant chemoradiotherapy and planned surgery, so-called interval metastases. The primary aim of this study was to assess management, overall survival (OS), and prognostic factors for OS in...

Cite
Kroese TE, Dijksterhuis WPM, van Rossum PSN, et al. Prognosis of Interval Distant Metastases After Neoadjuvant Chemoradiotherapy for Esophageal Cancer. Ann Thorac Surg. 2021;doi: 10.1016/j.athoracsur.2021.01.061.
Kroese, T. E., Dijksterhuis, W. P. M., van Rossum, P. S. N., Verhoeven, R. H. A., Mook, S., Haj Mohammad, N., Hulshof, M. C. C. M., van Berge Henegouwen, M. I., van Oijen, M. G. H., Ruurda, J. P., van Laarhoven, H. W. M., & van Hillegersberg, R. (2021). Prognosis of Interval Distant Metastases After Neoadjuvant Chemoradiotherapy for Esophageal Cancer. The Annals of thoracic surgery, . https://doi.org/10.1016/j.athoracsur.2021.01.061
Kroese, Tiuri E, et al. "Prognosis of Interval Distant Metastases After Neoadjuvant Chemoradiotherapy for Esophageal Cancer." The Annals of thoracic surgery vol. (2021). doi: https://doi.org/10.1016/j.athoracsur.2021.01.061
Kroese TE, Dijksterhuis WPM, van Rossum PSN, Verhoeven RHA, Mook S, Haj Mohammad N, Hulshof MCCM, van Berge Henegouwen MI, van Oijen MGH, Ruurda JP, van Laarhoven HWM, van Hillegersberg R. Prognosis of Interval Distant Metastases After Neoadjuvant Chemoradiotherapy for Esophageal Cancer. Ann Thorac Surg. 2021 Feb 18; doi: 10.1016/j.athoracsur.2021.01.061. Epub 2021 Feb 18. PMID: 33610543.
Copy Download .nbib Format: NLM
Postoperative intensive care unit stay after minimally invasive esophagectomy shows large hospital variation. Results from the Dutch Upper Gastrointestinal Cancer Audit.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Voeten DM, van der Werf LR, Gisbertz SS, Ruurda JP, van Berge Henegouwen MI, van Hillegersberg R.
PMID: 33485673
Eur J Surg Oncol. 2021 Aug;47(8):1961-1968. doi: 10.1016/j.ejso.2021.01.005. Epub 2021 Jan 16.

INTRODUCTION: The value of routine intensive care unit (ICU) admission after minimally invasive esophagectomy (MIE) has been questioned. This study aimed to investigate Dutch hospital variation regarding length of direct postoperative ICU stay, and the impact of this hospital...

Cite
Voeten DM, van der Werf LR, Gisbertz SS, et al. Postoperative intensive care unit stay after minimally invasive esophagectomy shows large hospital variation. Results from the Dutch Upper Gastrointestinal Cancer Audit. Eur J Surg Oncol. 2021;47(8):1961-1968doi: 10.1016/j.ejso.2021.01.005.
Voeten, D. M., van der Werf, L. R., Gisbertz, S. S., Ruurda, J. P., van Berge Henegouwen, M. I., van Hillegersberg, R. (2021). Postoperative intensive care unit stay after minimally invasive esophagectomy shows large hospital variation. Results from the Dutch Upper Gastrointestinal Cancer Audit. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 47(8), 1961-1968. https://doi.org/10.1016/j.ejso.2021.01.005
Voeten, Daan M, et al. "Postoperative intensive care unit stay after minimally invasive esophagectomy shows large hospital variation. Results from the Dutch Upper Gastrointestinal Cancer Audit." European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology vol. 47,8 (2021): 1961-1968. doi: https://doi.org/10.1016/j.ejso.2021.01.005
Voeten DM, van der Werf LR, Gisbertz SS, Ruurda JP, van Berge Henegouwen MI, van Hillegersberg R. Postoperative intensive care unit stay after minimally invasive esophagectomy shows large hospital variation. Results from the Dutch Upper Gastrointestinal Cancer Audit. Eur J Surg Oncol. 2021 Aug;47(8):1961-1968. doi: 10.1016/j.ejso.2021.01.005. Epub 2021 Jan 16. PMID: 33485673.
Copy Download .nbib Format: NLM
Risk Prediction Model of 90-Day Mortality After Esophagectomy for Cancer.

JAMA surgery

D'Journo XB, Boulate D, Fourdrain A, Loundou A, van Berge Henegouwen MI, Gisbertz SS, O'Neill JR, Hoelscher A, Piessen G, van Lanschot J, Wijnhoven B, Jobe B, Davies A, Schneider PM, Pera M, Nilsson M, Nafteux P, Kitagawa Y, Morse CR, Hofstetter W, Molena D, So JB, Immanuel A, Parsons SL, Larsen MH, Dolan JP, Wood SG, Maynard N, Smithers M, Puig S, Law S, Wong I, Kennedy A, KangNing W, Reynolds JV, Pramesh CS, Ferguson M, Darling G, Schröder W, Bludau M, Underwood T, van Hillegersberg R, Chang A, Cecconello I, Ribeiro U, de Manzoni G, Rosati R, Kuppusamy M, Thomas PA, Low DE.
PMID: 34160587
JAMA Surg. 2021 Sep 01;156(9):836-845. doi: 10.1001/jamasurg.2021.2376.

IMPORTANCE: Ninety-day mortality rates after esophagectomy are an indicator of the quality of surgical oncologic management. Accurate risk prediction based on large data sets may aid patients and surgeons in making informed decisions.OBJECTIVE: To develop and validate a risk...

Cite
D'Journo XB, Boulate D, Fourdrain A, et al. Risk Prediction Model of 90-Day Mortality After Esophagectomy for Cancer. JAMA Surg. 2021;156(9):836-845doi: 10.1001/jamasurg.2021.2376.
D'Journo, X. B., Boulate, D., Fourdrain, A., Loundou, A., van Berge Henegouwen, M. I., Gisbertz, S. S., O'Neill, J. R., Hoelscher, A., Piessen, G., van Lanschot, J., Wijnhoven, B., Jobe, B., Davies, A., Schneider, P. M., Pera, M., Nilsson, M., Nafteux, P., Kitagawa, Y., Morse, C. R., Hofstetter, W., Molena, D., So, J. B., Immanuel, A., Parsons, S. L., Larsen, M. H., Dolan, J. P., Wood, S. G., Maynard, N., Smithers, M., Puig, S., Law, S., Wong, I., Kennedy, A., KangNing, W., Reynolds, J. V., Pramesh, C. S., Ferguson, M., Darling, G., Schröder, W., Bludau, M., Underwood, T., van Hillegersberg, R., Chang, A., Cecconello, I., Ribeiro, U., de Manzoni, G., Rosati, R., Kuppusamy, M., Thomas, P. A., Low, D. E. (2021). Risk Prediction Model of 90-Day Mortality After Esophagectomy for Cancer. JAMA surgery, 156(9), 836-845. https://doi.org/10.1001/jamasurg.2021.2376
D'Journo, Xavier Benoit, et al. "Risk Prediction Model of 90-Day Mortality After Esophagectomy for Cancer." JAMA surgery vol. 156,9 (2021): 836-845. doi: https://doi.org/10.1001/jamasurg.2021.2376
D'Journo XB, Boulate D, Fourdrain A, Loundou A, van Berge Henegouwen MI, Gisbertz SS, O'Neill JR, Hoelscher A, Piessen G, van Lanschot J, Wijnhoven B, Jobe B, Davies A, Schneider PM, Pera M, Nilsson M, Nafteux P, Kitagawa Y, Morse CR, Hofstetter W, Molena D, So JB, Immanuel A, Parsons SL, Larsen MH, Dolan JP, Wood SG, Maynard N, Smithers M, Puig S, Law S, Wong I, Kennedy A, KangNing W, Reynolds JV, Pramesh CS, Ferguson M, Darling G, Schröder W, Bludau M, Underwood T, van Hillegersberg R, Chang A, Cecconello I, Ribeiro U, de Manzoni G, Rosati R, Kuppusamy M, Thomas PA, Low DE. Risk Prediction Model of 90-Day Mortality After Esophagectomy for Cancer. JAMA Surg. 2021 Sep 01;156(9):836-845. doi: 10.1001/jamasurg.2021.2376. PMID: 34160587; PMCID: PMC8223144.
Copy Download .nbib Format: NLM
NEOadjuvant therapy monitoring with PET and CT in Esophageal Cancer (NEOPEC-trial).

BMC medical physics

van Heijl M, Omloo JM, van Berge Henegouwen MI, Busch OR, Tilanus HW, Bossuyt PM, Hoekstra OS, Stoker J, Hulshof MC, van der Gaast A, Nieuwenhuijzen GA, Bonenkamp HJ, Plukker JT, Bilgen EJ, Ten Kate FJ, Boellaard R, Pruim J, Sloof GW, van Lanschot JJ.
PMID: 18671847
BMC Med Phys. 2008 Jul 31;8:3. doi: 10.1186/1756-6649-8-3.

BACKGROUND: Surgical resection is the preferred treatment of potentially curable esophageal cancer. To improve long term patient outcome, many institutes apply neoadjuvant chemoradiotherapy. In a large proportion of patients no response to chemoradiotherapy is achieved. These patients suffer from...

Cite
van Heijl M, Omloo JM, van Berge Henegouwen MI, et al. NEOadjuvant therapy monitoring with PET and CT in Esophageal Cancer (NEOPEC-trial). BMC Med Phys. 2008;8:3doi: 10.1186/1756-6649-8-3.
van Heijl, M., Omloo, J. M., van Berge Henegouwen, M. I., Busch, O. R., Tilanus, H. W., Bossuyt, P. M., Hoekstra, O. S., Stoker, J., Hulshof, M. C., van der Gaast, A., Nieuwenhuijzen, G. A., Bonenkamp, H. J., Plukker, J. T., Bilgen, E. J., Ten Kate, F. J., Boellaard, R., Pruim, J., Sloof, G. W., & van Lanschot, J. J. (2008). NEOadjuvant therapy monitoring with PET and CT in Esophageal Cancer (NEOPEC-trial). BMC medical physics, 83. https://doi.org/10.1186/1756-6649-8-3
van Heijl, Mark, et al. "NEOadjuvant therapy monitoring with PET and CT in Esophageal Cancer (NEOPEC-trial)." BMC medical physics vol. 8 (2008): 3. doi: https://doi.org/10.1186/1756-6649-8-3
van Heijl M, Omloo JM, van Berge Henegouwen MI, Busch OR, Tilanus HW, Bossuyt PM, Hoekstra OS, Stoker J, Hulshof MC, van der Gaast A, Nieuwenhuijzen GA, Bonenkamp HJ, Plukker JT, Bilgen EJ, Ten Kate FJ, Boellaard R, Pruim J, Sloof GW, van Lanschot JJ. NEOadjuvant therapy monitoring with PET and CT in Esophageal Cancer (NEOPEC-trial). BMC Med Phys. 2008 Jul 31;8:3. doi: 10.1186/1756-6649-8-3. PMID: 18671847; PMCID: PMC3301128.
Copy Download .nbib Format: NLM
Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT).

Clinical cancer research : an official journal of the American Association for Cancer Research

van den Ende T, de Clercq NC, van Berge Henegouwen MI, Gisbertz SS, Geijsen ED, Verhoeven RHA, Meijer SL, Schokker S, Dings MPG, Bergman JJGHM, Haj Mohammad N, Ruurda JP, van Hillegersberg R, Mook S, Nieuwdorp M, de Gruijl TD, Soeratram TTD, Ylstra B, van Grieken NCT, Bijlsma MF, Hulshof MCCM, van Laarhoven HWM.
PMID: 33504550
Clin Cancer Res. 2021 Jun 15;27(12):3351-3359. doi: 10.1158/1078-0432.CCR-20-4443. Epub 2021 Jan 27.

PURPOSE: The CROSS trial established neoadjuvant chemoradiotherapy (nCRT) for patients with resectable esophageal adenocarcinoma (rEAC). In the PERFECT trial, we investigated the feasibility and efficacy of nCRT combined with programmed-death ligand-1 (PD-L1) inhibition for rEAC.PATIENTS AND METHODS: Patients with...

Cite
van den Ende T, de Clercq NC, van Berge Henegouwen MI, et al. Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT). Clin Cancer Res. 2021;27(12):3351-3359doi: 10.1158/1078-0432.CCR-20-4443.
van den Ende, T., de Clercq, N. C., van Berge Henegouwen, M. I., Gisbertz, S. S., Geijsen, E. D., Verhoeven, R. H. A., Meijer, S. L., Schokker, S., Dings, M. P. G., Bergman, J. J. G. H. M., Haj Mohammad, N., Ruurda, J. P., van Hillegersberg, R., Mook, S., Nieuwdorp, M., de Gruijl, T. D., Soeratram, T. T. D., Ylstra, B., van Grieken, N. C. T., Bijlsma, M. F., Hulshof, M. C. C. M., & van Laarhoven, H. W. M. (2021). Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT). Clinical cancer research : an official journal of the American Association for Cancer Research, 27(12), 3351-3359. https://doi.org/10.1158/1078-0432.CCR-20-4443
van den Ende, Tom, et al. "Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT)." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,12 (2021): 3351-3359. doi: https://doi.org/10.1158/1078-0432.CCR-20-4443
van den Ende T, de Clercq NC, van Berge Henegouwen MI, Gisbertz SS, Geijsen ED, Verhoeven RHA, Meijer SL, Schokker S, Dings MPG, Bergman JJGHM, Haj Mohammad N, Ruurda JP, van Hillegersberg R, Mook S, Nieuwdorp M, de Gruijl TD, Soeratram TTD, Ylstra B, van Grieken NCT, Bijlsma MF, Hulshof MCCM, van Laarhoven HWM. Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT). Clin Cancer Res. 2021 Jun 15;27(12):3351-3359. doi: 10.1158/1078-0432.CCR-20-4443. Epub 2021 Jan 27. PMID: 33504550.
Copy Download .nbib Format: NLM
Prognostic relevance of lymph node regression on survival in esophageal cancer: a systematic review and meta-analysis.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus

Hagens E, Tukanova K, Jamel S, van Berge Henegouwen M, Hanna GB, Gisbertz S, Markar SR.
PMID: 33893494
Dis Esophagus. 2022 Jan 07;35(1). doi: 10.1093/dote/doab021.

INTRODUCTION: The prognostic value of histomorphologic regression in primary esophageal cancer has been previously established, however the impact of lymph node (LN) response on survival still remains unclear. The aim of this review was to assess the prognostic significance...

Cite
Hagens E, Tukanova K, Jamel S, et al. Prognostic relevance of lymph node regression on survival in esophageal cancer: a systematic review and meta-analysis. Dis Esophagus. 2022;35(1)doi: 10.1093/dote/doab021.
Hagens, E., Tukanova, K., Jamel, S., van Berge Henegouwen, M., Hanna, G. B., Gisbertz, S., & Markar, S. R. (2022). Prognostic relevance of lymph node regression on survival in esophageal cancer: a systematic review and meta-analysis. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 35(1), . https://doi.org/10.1093/dote/doab021
Hagens, Eliza, et al. "Prognostic relevance of lymph node regression on survival in esophageal cancer: a systematic review and meta-analysis." Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus vol. 35,1 (2022). doi: https://doi.org/10.1093/dote/doab021
Hagens E, Tukanova K, Jamel S, van Berge Henegouwen M, Hanna GB, Gisbertz S, Markar SR. Prognostic relevance of lymph node regression on survival in esophageal cancer: a systematic review and meta-analysis. Dis Esophagus. 2022 Jan 07;35(1). doi: 10.1093/dote/doab021. PMID: 33893494; PMCID: PMC8752080.
Copy Download .nbib Format: NLM
Risk Prediction Model of 90-Day Mortality After Esophagectomy for Cancer.

JAMA surgery

D'Journo XB, Boulate D, Fourdrain A, Loundou A, van Berge Henegouwen MI, Gisbertz SS, O'Neill JR, Hoelscher A, Piessen G, van Lanschot J, Wijnhoven B, Jobe B, Davies A, Schneider PM, Pera M, Nilsson M, Nafteux P, Kitagawa Y, Morse CR, Hofstetter W, Molena D, So JB, Immanuel A, Parsons SL, Larsen MH, Dolan JP, Wood SG, Maynard N, Smithers M, Puig S, Law S, Wong I, Kennedy A, KangNing W, Reynolds JV, Pramesh CS, Ferguson M, Darling G, Schröder W, Bludau M, Underwood T, van Hillegersberg R, Chang A, Cecconello I, Ribeiro U, de Manzoni G, Rosati R, Kuppusamy M, Thomas PA, Low DE.
PMID: 34160587
JAMA Surg. 2021 Sep 01;156(9):836-845. doi: 10.1001/jamasurg.2021.2376.

IMPORTANCE: Ninety-day mortality rates after esophagectomy are an indicator of the quality of surgical oncologic management. Accurate risk prediction based on large data sets may aid patients and surgeons in making informed decisions.OBJECTIVE: To develop and validate a risk...

Cite
D'Journo XB, Boulate D, Fourdrain A, et al. Risk Prediction Model of 90-Day Mortality After Esophagectomy for Cancer. JAMA Surg. 2021;156(9):836-845doi: 10.1001/jamasurg.2021.2376.
D'Journo, X. B., Boulate, D., Fourdrain, A., Loundou, A., van Berge Henegouwen, M. I., Gisbertz, S. S., O'Neill, J. R., Hoelscher, A., Piessen, G., van Lanschot, J., Wijnhoven, B., Jobe, B., Davies, A., Schneider, P. M., Pera, M., Nilsson, M., Nafteux, P., Kitagawa, Y., Morse, C. R., Hofstetter, W., Molena, D., So, J. B., Immanuel, A., Parsons, S. L., Larsen, M. H., Dolan, J. P., Wood, S. G., Maynard, N., Smithers, M., Puig, S., Law, S., Wong, I., Kennedy, A., KangNing, W., Reynolds, J. V., Pramesh, C. S., Ferguson, M., Darling, G., Schröder, W., Bludau, M., Underwood, T., van Hillegersberg, R., Chang, A., Cecconello, I., Ribeiro, U., de Manzoni, G., Rosati, R., Kuppusamy, M., Thomas, P. A., Low, D. E. (2021). Risk Prediction Model of 90-Day Mortality After Esophagectomy for Cancer. JAMA surgery, 156(9), 836-845. https://doi.org/10.1001/jamasurg.2021.2376
D'Journo, Xavier Benoit, et al. "Risk Prediction Model of 90-Day Mortality After Esophagectomy for Cancer." JAMA surgery vol. 156,9 (2021): 836-845. doi: https://doi.org/10.1001/jamasurg.2021.2376
D'Journo XB, Boulate D, Fourdrain A, Loundou A, van Berge Henegouwen MI, Gisbertz SS, O'Neill JR, Hoelscher A, Piessen G, van Lanschot J, Wijnhoven B, Jobe B, Davies A, Schneider PM, Pera M, Nilsson M, Nafteux P, Kitagawa Y, Morse CR, Hofstetter W, Molena D, So JB, Immanuel A, Parsons SL, Larsen MH, Dolan JP, Wood SG, Maynard N, Smithers M, Puig S, Law S, Wong I, Kennedy A, KangNing W, Reynolds JV, Pramesh CS, Ferguson M, Darling G, Schröder W, Bludau M, Underwood T, van Hillegersberg R, Chang A, Cecconello I, Ribeiro U, de Manzoni G, Rosati R, Kuppusamy M, Thomas PA, Low DE. Risk Prediction Model of 90-Day Mortality After Esophagectomy for Cancer. JAMA Surg. 2021 Sep 01;156(9):836-845. doi: 10.1001/jamasurg.2021.2376. PMID: 34160587; PMCID: PMC8223144.
Copy Download .nbib Format: NLM
Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol.

JMIR research protocols

Noordman BJ, Shapiro J, Spaander MC, Krishnadath KK, van Laarhoven HW, van Berge Henegouwen MI, Nieuwenhuijzen GA, van Hillegersberg R, Sosef MN, Steyerberg EW, Wijnhoven BP, van Lanschot JJ.
PMID: 26121676
JMIR Res Protoc. 2015 Jun 29;4(2):e79. doi: 10.2196/resprot.4320.

BACKGROUND: Results from the recent CROSS trial showed that neoadjuvant chemoradiotherapy (nCRT) significantly increased survival as compared to surgery alone in patients with potentially curable esophageal cancer. Furthermore, in the nCRT arm 49% of patients with a squamous cell...

Cite
Noordman BJ, Shapiro J, Spaander MC, et al. Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol. JMIR Res Protoc. 2015;4(2):e79doi: 10.2196/resprot.4320.
Noordman, B. J., Shapiro, J., Spaander, M. C., Krishnadath, K. K., van Laarhoven, H. W., van Berge Henegouwen, M. I., Nieuwenhuijzen, G. A., van Hillegersberg, R., Sosef, M. N., Steyerberg, E. W., Wijnhoven, B. P., van Lanschot, J. J. (2015). Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol. JMIR research protocols, 4(2), e79. https://doi.org/10.2196/resprot.4320
Noordman, Bo Jan, et al. "Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol." JMIR research protocols vol. 4,2 (2015): e79. doi: https://doi.org/10.2196/resprot.4320
Noordman BJ, Shapiro J, Spaander MC, Krishnadath KK, van Laarhoven HW, van Berge Henegouwen MI, Nieuwenhuijzen GA, van Hillegersberg R, Sosef MN, Steyerberg EW, Wijnhoven BP, van Lanschot JJ. Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol. JMIR Res Protoc. 2015 Jun 29;4(2):e79. doi: 10.2196/resprot.4320. PMID: 26121676; PMCID: PMC4526968.
Copy Download .nbib Format: NLM
Acute Pancreatitis in the Postoperative Course after Esophagectomy: A Major Complication Described in 4 Patients.

Case reports in gastroenterology

Blom RL, van Heijl M, Busch OR, van Berge Henegouwen MI.
PMID: 21103258
Case Rep Gastroenterol. 2009 Nov 21;3(3):382-388. doi: 10.1159/000258092.

BACKGROUND: Postoperative pancreatitis is a rare but devastating complication after esophageal surgery. It has been described in connection with abdominal surgery but the etiology in connection with esophageal surgery has never been evaluated. The present study describes 4 cases...

Cite
Blom RL, van Heijl M, Busch OR, et al. Acute Pancreatitis in the Postoperative Course after Esophagectomy: A Major Complication Described in 4 Patients. Case Rep Gastroenterol. 2009;3(3):382-388doi: 10.1159/000258092.
Blom, R. L., van Heijl, M., Busch, O. R., & van Berge Henegouwen, M. I. (2009). Acute Pancreatitis in the Postoperative Course after Esophagectomy: A Major Complication Described in 4 Patients. Case reports in gastroenterology, 3(3), 382-388. https://doi.org/10.1159/000258092
Blom, R L G M, et al. "Acute Pancreatitis in the Postoperative Course after Esophagectomy: A Major Complication Described in 4 Patients." Case reports in gastroenterology vol. 3,3 (2009): 382-388. doi: https://doi.org/10.1159/000258092
Blom RL, van Heijl M, Busch OR, van Berge Henegouwen MI. Acute Pancreatitis in the Postoperative Course after Esophagectomy: A Major Complication Described in 4 Patients. Case Rep Gastroenterol. 2009 Nov 21;3(3):382-388. doi: 10.1159/000258092. PMID: 21103258; PMCID: PMC2988934.
Copy Download .nbib Format: NLM
Erratum: Resection of hepatic and pulmonary metastasis from metastatic esophageal and gastric cancer: a nationwide study.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus

Seesing MFJ, van der Veen A, Brenkman HJF, Stockmann HBAC, Nieuwenhuijzen GAP, Rosman C, van den Wildenberg FJH, van Berge Henegouwen MI, van Duijvendijk P, Wijnhoven BPL, Stoot JHMB, Lacle M, Ruurda JP, van Hillegersberg R.
PMID: 31504355
Dis Esophagus. 2019 Nov 13;32(9). doi: 10.1093/dote/doz069.

No abstract available.

Cite
Seesing MFJ, van der Veen A, Brenkman HJF, et al. Erratum: Resection of hepatic and pulmonary metastasis from metastatic esophageal and gastric cancer: a nationwide study. Dis Esophagus. 2019;32(9)doi: 10.1093/dote/doz069.
Seesing, M. F. J., van der Veen, A., Brenkman, H. J. F., Stockmann, H. B. A. C., Nieuwenhuijzen, G. A. P., Rosman, C., van den Wildenberg, F. J. H., van Berge Henegouwen, M. I., van Duijvendijk, P., Wijnhoven, B. P. L., Stoot, J. H. M. B., Lacle, M., Ruurda, J. P., van Hillegersberg, R. (2019). Erratum: Resection of hepatic and pulmonary metastasis from metastatic esophageal and gastric cancer: a nationwide study. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 32(9), . https://doi.org/10.1093/dote/doz069
Seesing, M F J, et al. "Erratum: Resection of hepatic and pulmonary metastasis from metastatic esophageal and gastric cancer: a nationwide study." Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus vol. 32,9 (2019). doi: https://doi.org/10.1093/dote/doz069
Seesing MFJ, van der Veen A, Brenkman HJF, Stockmann HBAC, Nieuwenhuijzen GAP, Rosman C, van den Wildenberg FJH, van Berge Henegouwen MI, van Duijvendijk P, Wijnhoven BPL, Stoot JHMB, Lacle M, Ruurda JP, van Hillegersberg R. Erratum: Resection of hepatic and pulmonary metastasis from metastatic esophageal and gastric cancer: a nationwide study. Dis Esophagus. 2019 Nov 13;32(9). doi: 10.1093/dote/doz069. PMID: 31504355; PMCID: PMC7729205.
Copy Download .nbib Format: NLM
Extensive thoracoscopic mediastinal lymph node dissection on the left side: how it should be done.

Journal of thoracic disease

Heineman DJ, van Berge Henegouwen MI.
PMID: 30863573
J Thorac Dis. 2019 Jan;11(1):62-64. doi: 10.21037/jtd.2019.01.09.

No abstract available.

Cite
Heineman DJ, van Berge Henegouwen MI. Extensive thoracoscopic mediastinal lymph node dissection on the left side: how it should be done. J Thorac Dis. 2019;11(1):62-64doi: 10.21037/jtd.2019.01.09.
Heineman, D. J., & van Berge Henegouwen, M. I. (2019). Extensive thoracoscopic mediastinal lymph node dissection on the left side: how it should be done. Journal of thoracic disease, 11(1), 62-64. https://doi.org/10.21037/jtd.2019.01.09
Heineman, David J, and van Berge Henegouwen, Mark I. "Extensive thoracoscopic mediastinal lymph node dissection on the left side: how it should be done." Journal of thoracic disease vol. 11,1 (2019): 62-64. doi: https://doi.org/10.21037/jtd.2019.01.09
Heineman DJ, van Berge Henegouwen MI. Extensive thoracoscopic mediastinal lymph node dissection on the left side: how it should be done. J Thorac Dis. 2019 Jan;11(1):62-64. doi: 10.21037/jtd.2019.01.09. PMID: 30863573; PMCID: PMC6384359.
Copy Download .nbib Format: NLM
The dynamics of HER2 status in esophageal adenocarcinoma.

Oncotarget

Creemers A, Ebbing EA, Hooijer GKJ, Stap L, Jibodh-Mulder RA, Gisbertz SS, van Berge Henegouwen MI, van Montfoort ML, Hulshof MCCM, Krishnadath KK, van Oijen MGH, Bijlsma MF, Meijer SL, van Laarhoven HWM.
PMID: 29928485
Oncotarget. 2018 Jun 01;9(42):26787-26799. doi: 10.18632/oncotarget.25507. eCollection 2018 Jun 01.

Trastuzumab, a monoclonal antibody against HER2, has become standard of care for metastatic HER2-overexpressing esophagogastric adenocarcinoma and is currently investigated as (neo)adjuvant treatment option in HER2-positive esophagogastric adenocarcinoma. The HER2 status is commonly determined on archived material of the...

Cite
Creemers A, Ebbing EA, Hooijer GKJ, et al. The dynamics of HER2 status in esophageal adenocarcinoma. Oncotarget. 2018;9(42):26787-26799doi: 10.18632/oncotarget.25507.
Creemers, A., Ebbing, E. A., Hooijer, G. K. J., Stap, L., Jibodh-Mulder, R. A., Gisbertz, S. S., van Berge Henegouwen, M. I., van Montfoort, M. L., Hulshof, M. C. C. M., Krishnadath, K. K., van Oijen, M. G. H., Bijlsma, M. F., Meijer, S. L., & van Laarhoven, H. W. M. (2018). The dynamics of HER2 status in esophageal adenocarcinoma. Oncotarget, 9(42), 26787-26799. https://doi.org/10.18632/oncotarget.25507
Creemers, Aafke, et al. "The dynamics of HER2 status in esophageal adenocarcinoma." Oncotarget vol. 9,42 (2018): 26787-26799. doi: https://doi.org/10.18632/oncotarget.25507
Creemers A, Ebbing EA, Hooijer GKJ, Stap L, Jibodh-Mulder RA, Gisbertz SS, van Berge Henegouwen MI, van Montfoort ML, Hulshof MCCM, Krishnadath KK, van Oijen MGH, Bijlsma MF, Meijer SL, van Laarhoven HWM. The dynamics of HER2 status in esophageal adenocarcinoma. Oncotarget. 2018 Jun 01;9(42):26787-26799. doi: 10.18632/oncotarget.25507. eCollection 2018 Jun 01. PMID: 29928485; PMCID: PMC6003553.
Copy Download .nbib Format: NLM
Showing 49 to 60 of 70 entries